

## 1. Introduction

We regularly work with healthcare professionals (HCPs) and healthcare organisations (HCOs) who advise us on a range of topics such as medicines development, the role of a medicine in a patient treatment pathway; health economics and clinical best practice. These working relationships are essential to gaining the real-world information we need in order to deliver treatment choices that improve the health of patients and to share information that may be relevant to clinical decision making. We want people to know, and understand, what we do and how we do it. We are committed to transparency about how we operate as a business and about the relationships we have with HCPs and HCOs. Sharing information about these relationships in a straightforward and open way will, we hope, help explain the critical value these relationships bring to patient management. We believe that transparency is essential to building and maintaining confidence in us and in our medicines and strongly support the work being done by The European Federation of Pharmaceutical Industries and Associations (EFPIA) to improve transparency across the pharmaceutical industry. The EFPIA Disclosure Code provides a common basis for reporting across Europe in relation to transfers of value. Disclosure of payments made to Irish HCPs and HCOs for events held in 2015 will be available at the end of June 2016. These timelines will apply for all subsequent reporting periods hereafter. This report discloses all the transfers of value made to Health Care Professionals (HCPs) and Health Care Organisations (HCOs) in 2016. This methodological note presents some of the key aspects of how the transfers of value are categorised and in what format they are disclosed. The transfers of value disclosed in this report cover all the payments made by Galderma to HCPs and HCOs residing in Ireland. The report is published by Galderma (UK) Ltd and is in line with the Irish Pharmaceutical Healthcare Association (IPHA) and meets the reporting requirements of the EFPIA Disclosure Code and the Association of British Pharmaceutical Industries (ABPI) Code of Practice.

## 2. Galderma activities per EFPIA category

EFPIA Category	EFPIA subcategory	Activities
Donations and Grants (HCOs only)	n/a	<ul style="list-style-type: none"><li>- Charitable contributions</li><li>- Business Donations</li><li>- Educational grants (e.g. fellowships, courses provided by a HCO where Galderma does not select the individual HCPs participating)</li><li>- Sponsoring of speakers/faculty which by nature of purpose and funding are classified under educational grants</li></ul>
Contribution to Cost of Events	Sponsorship agreements (HCOs only)	<ul style="list-style-type: none"><li>- Placement of a brand logo in a conference program or invitation communication in exchange for supporting the program</li><li>- Funding an event in return for a display booth</li><li>- Funding an event in exchange for advertising space</li><li>- Other advertisement space (in paper, electronic or other</li></ul>

		format) - Satellite symposia at a congress - If part of a package: Name badges, drinks, meals etc. provided by the organisers (included in the sponsorship agreement)
	Registration fees	- Fees paid for the HCP/HCO to attend events not organised by Galderma
	Travel & Accommodation	- Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking) - Accommodation
Fee for services and consultancy	Fees	- Speaker engagements - Advisory Boards - Study-related - Post-marketing surveillance studies - Medical writing - Data analysis - Development of education materials - General consulting / advising - Speaker training if linked to a speaker engagement
	Related expenses	- Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking) - Accommodation
Research and Development Transfers of Value	n/a	Clinical Trials - Data Monitoring Committees related to studies - Non Interventional Studies - Investigators Initiated Research (IIR) - Clinical & Research Collaboration

### 3. Sources of information

The transfers of value are collected from the internal and external data sources and systems and then fed into a central database where data is validated and the disclosure reports are generated.

### 4. Definition of the Transfers of Value

This section outlines some key aspects of how the transfers of value are defined.

**Definition of HCP:**

“Healthcare Professionals” (HCP) shall mean physicians and pharmacists based in Europe and exercising their professional activities there on a full-time basis as well as any member of the medical, dental, pharmacy or other nursing professions or any other person who in the course of his or her professional activities may prescribe or apply or lawfully trade in medicinal products for human use.

**Definition of HCO:**

“HCOs are defined as any healthcare, medical or scientific association or organisation (irrespective of the legal or organisational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for patient organisations within the scope of Annex III of the IPHA Code) whose business address, place of incorporation or primary place of operation is in Europe or (ii) through which one or more HCPs provide services.”

**5. Date of transfer of value**

Galderma (UK) Ltd will disclose all payments made to HCPs/HCOs for events which took place in 2016.